APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Anthracycline APIs

Anthracycline APIs are cytotoxic antineoplastic active pharmaceutical ingredients in the WHO ATC L01DB anthracycline class, used as the drug-substance basis for sterile oncology products.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Anthracycline APIs are cytotoxic antineoplastic active pharmaceutical ingredients in the WHO ATC L01DB anthracycline class, used as the drug-substance basis for sterile oncology products. In commercial API terms, the category mainly covers doxorubicin, daunorubicin, epirubicin, idarubicin, and, in some markets, pirarubicin. These compounds share the anthracycline core architecture: a tetracyclic anthraquinone-type aglycone linked through a glycosidic bond to an amino sugar, typically daunosamine. They are commonly supplied as hydrochloride salts, including doxorubicin hydrochloride, daunorubicin hydrochloride, epirubicin hydrochloride, and idarubicin hydrochloride, because the finished products are predominantly parenteral cytotoxic formulations. Their pharmacological activity is driven by DNA intercalation and topoisomerase II inhibition, with consequent inhibition of nucleic acid synthesis and tumor-cell death.

Anthracycline APIs belong to the classical fermentation-based antitumor antibiotic segment of the pharmaceutical industry. Industrial production starts with microbial biosynthesis using Streptomyces strains, followed by extraction from the fermentation broth, multistep purification, salt formation, and tight control of related substances and potency. Doxorubicin is officially described in FDA labeling as an anthracycline topoisomerase inhibitor isolated from cultures of Streptomyces peucetius var. caesius, while daunorubicin is likewise a fermentation-derived anthracycline. Commercial derivatives are then obtained through downstream chemical transformation where needed; epirubicin, for example, is officially described as the 4-epimer of doxorubicin and a semi-synthetic derivative, and patent literature describes industrial epirubicin preparation from daunorubicin or epidaunorubicin intermediates. In practice, this makes anthracycline API manufacturing a hybrid platform combining fermentation, high-purity isolation, semisynthetic conversion, crystallization, and stringent GMP control suitable for injectable oncology use.

Therapeutically, anthracycline APIs support a broad oncology indication set spanning both hematologic malignancies and solid tumors. Daunorubicin and idarubicin are established leukemia anthracyclines, especially in acute myeloid leukemia and, depending on product labeling, acute lymphoblastic leukemia. Doxorubicin has one of the broadest label footprints in the class, covering breast cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, acute leukemias, soft tissue sarcoma, bone sarcoma, Wilms tumor, and neuroblastoma, while epirubicin is a core breast-cancer anthracycline in adjuvant therapy. Across the class, clinical utility is balanced by well-defined dose-limiting toxicities, particularly myelosuppression and cumulative cardiotoxicity, which is why anthracycline APIs are handled as highly controlled cytotoxic drug substances throughout development, manufacture, and clinical use.

The research object may be an ingredient, device, preparation or care service. These supply stages have different specifications and measurement units; an ingredient identity or device name does not establish a clinical outcome.

What turns activity into demand

Qualified use at the specified treatment or instrument boundary creates purchases through protocol, utilisation and replacement. A product, clinical service and complete care episode measure different supplied objects.

The commercial boundary

For Anthracycline APIs, distinguish the supplied product from its inputs and the complete application. Report types and applications may overlap; retain the selected edition's product definition, geography, period, unit and transaction basis when comparing estimates.

Which conditions determine usable anthracycline apis performance?

Anthracycline APIs are cytotoxic antineoplastic active pharmaceutical ingredients in the WHO ATC L01DB anthracycline class, used as the drug-substance basis for sterile oncology products. Confirm the specified composition or device function, intended use and supplied unit. Separate ingredients, finished preparations, equipment and treatment activity before comparing quantities or revenue; use the report scope rather than inferring efficacy from an illustration.

Selected research

Market Structure

Global Anthracycline APIs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17389352033 August 2026193 pages

Choose your research edition.

Industry ResearchAnthracycline APIs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Anthracycline APIs Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Anthracycline APIs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anthracycline APIs Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Anthracycline APIs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Anthracycline APIs are cytotoxic antineoplastic active pharmaceutical ingredients in the WHO ATC L01DB anthracycline class, used as the drug-substance basis for sterile oncology products. In commercial API terms, the category mainly covers doxorubicin, daunorubicin, epirubicin, idarubicin, and, in some markets, pirarubicin. These compounds share the anthracycline core architecture: a tetracyclic anthraquinone-type aglycone linked through a glycosidic bond to an amino sugar, typically daunosamine. They are commonly supplied as hydrochloride salts, including doxorubicin hydrochloride, daunorubicin hydrochloride, epirubicin hydrochloride, and idarubicin hydrochloride, because the finished products are predominantly parenteral cytotoxic formulations. Their pharmacological activity is driven by DNA intercalation and topoisomerase II inhibition, with consequent inhibition of nucleic acid synthesis and tumor-cell death.

Anthracycline APIs belong to the classical fermentation-based antitumor antibiotic segment of the pharmaceutical industry. Industrial production starts with microbial biosynthesis using Streptomyces strains, followed by extraction from the fermentation broth, multistep purification, salt formation, and tight control of related substances and potency. Doxorubicin is officially described in FDA labeling as an anthracycline topoisomerase inhibitor isolated from cultures of Streptomyces peucetius var. caesius, while daunorubicin is likewise a fermentation-derived anthracycline. Commercial derivatives are then obtained through downstream chemical transformation where needed; epirubicin, for example, is officially described as the 4-epimer of doxorubicin and a semi-synthetic derivative, and patent literature describes industrial epirubicin preparation from daunorubicin or epidaunorubicin intermediates. In practice, this makes anthracycline API manufacturing a hybrid platform combining fermentation, high-purity isolation, semisynthetic conversion, crystallization, and stringent GMP control suitable for injectable oncology use.

Therapeutically, anthracycline APIs support a broad oncology indication set spanning both hematologic malignancies and solid tumors. Daunorubicin and idarubicin are established leukemia anthracyclines, especially in acute myeloid leukemia and, depending on product labeling, acute lymphoblastic leukemia. Doxorubicin has one of the broadest label footprints in the class, covering breast cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, acute leukemias, soft tissue sarcoma, bone sarcoma, Wilms tumor, and neuroblastoma, while epirubicin is a core breast-cancer anthracycline in adjuvant therapy. Across the class, clinical utility is balanced by well-defined dose-limiting toxicities, particularly myelosuppression and cumulative cardiotoxicity, which is why anthracycline APIs are handled as highly controlled cytotoxic drug substances throughout development, manufacture, and clinical use.

Read the full market overview

The global Anthracycline APIs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anthracycline APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anthracycline APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Anthracycline APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anthracycline APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anthracycline APIs include Synbias-Gemini, Intas Pharma, MicroBiopharm Japan, TAPI, Humble Healthcaare, Sterling Biotech, Olon S.p.A., Lunan Pharmaceutical and DZD (Heze) Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anthracycline APIs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anthracycline APIs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anthracycline APIs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anthracycline APIs market size, projected growth trends, production technologies, key applications, and end-use industries.

Anthracycline APIs Segment by Company

Synbias-Gemini

Intas Pharma

MicroBiopharm Japan

TAPI

Humble Healthcaare

Sterling Biotech

Olon S.p.A.

Lunan Pharmaceutical

DZD (Heze) Pharmaceutical

Zhejiang Hisun

Meiji Seika Pharma

Anthracycline APIs Segment by Type

Doxorubicin API

Daunorubicin API

Epirubicin API

Idarubicin API

Pirarubicin API

Other

Anthracycline APIs Segment by Application

Solid Tumors

Hematologic Malignancies

Others

Anthracycline APIs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anthracycline APIs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anthracycline APIs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anthracycline APIs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anthracycline APIs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anthracycline APIs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anthracycline APIs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anthracycline APIs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anthracycline APIs Industry Trends Table 2. Anthracycline APIs Industry Drivers Table 3. Anthracycline APIs Industry Opportunities and Challenges Table 4. Anthracycline APIs Industry Restraints Table 5. Global Anthracycline APIs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anthracycline APIs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anthracycline APIs Sales by Manufacturers (kg) & (2021-2026) Table 8. Global Anthracycline APIs Sales Market Share by Manufacturers Table 9. Global Anthracycline APIs Average Sales Price (USD/g) of Manufacturers (2021-2026) Table 10. Global Anthracycline APIs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anthracycline APIs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anthracycline APIs Manufacturers, Product Type & Application Table 13. Global Anthracycline APIs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anthracycline APIs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Doxorubicin API Table 17. Major Manufacturers of Daunorubicin API Table 18. Major Manufacturers of Epirubicin API Table 19. Major Manufacturers of Idarubicin API Table 20. Major Manufacturers of Pirarubicin API Table 21. Major Manufacturers of Other Table 22. Global Anthracycline APIs Sales by Type 2021 VS 2025 VS 2032 (kg) Table 23. Global Anthracycline APIs Sales by Type (2021-2026) & (kg) Table 24. Global Anthracycline APIs Sales by Type (2027-2032) & (kg) Table 25. Global Anthracycline APIs Sales Market Share by Type (2021-2026) Table 26. Global Anthracycline APIs Sales Market Share by Type (2027-2032) Table 27. Global Anthracycline APIs Revenue by Type 2021 VS 2025 VS 2032 (kg) Table 28. Global Anthracycline APIs Revenue by Type (2021-2026) & (kg) Table 29. Global Anthracycline APIs Revenue by Type (2027-2032) & (kg) Table 30. Global Anthracycline APIs Revenue Market Share by Type (2021-2026) Table 31. Global Anthracycline APIs Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Solid Tumors Table 33. Major Manufacturers of Hematologic Malignancies Table 34. Major Manufacturers of Others Table 35. Global Anthracycline APIs Sales by Application 2021 VS 2025 VS 2032 (kg) Table 36. Global Anthracycline APIs Sales by Application (2021-2026) & (kg) Table 37. Global Anthracycline APIs Sales by Application (2027-2032) & (kg) Table 38. Global Anthracycline APIs Sales Market Share by Application (2021-2026) Table 39. Global Anthracycline APIs Sales Market Share by Application (2027-2032) Table 40. Global Anthracycline APIs Revenue by Application 2021 VS 2025 VS 2032 (kg) Table 41. Global Anthracycline APIs Revenue by Application (2021-2026) & (kg) Table 42. Global Anthracycline APIs Revenue by Application (2027-2032) & (kg) Table 43. Global Anthracycline APIs Revenue Market Share by Application (2021-2026) Table 44. Global Anthracycline APIs Revenue Market Share by Application (2027-2032) Table 45. Global Anthracycline APIs Sales by Region: 2021 VS 2025 VS 2032 (kg) Table 46. Global Anthracycline APIs Sales by Region (2021-2026) & (kg) Table 47. Global Anthracycline APIs Sales Market Share by Region (2021-2026) Table 48. Global Anthracycline APIs Sales Forecasted by Region (2027-2032) & (kg) Table 49. Global Anthracycline APIs Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Anthracycline APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 51. North America Anthracycline APIs Sales by Country (2021-2026) & (kg) Table 52. North America Anthracycline APIs Sales by Country (2027-2032) & (kg) Table 53. Europe Anthracycline APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 54. Europe Anthracycline APIs Sales by Country (2021-2026) & (kg) Table 55. Europe Anthracycline APIs Sales by Country (2027-2032) & (kg) Table 56. Asia Pacific Anthracycline APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 57. Asia Pacific Anthracycline APIs Sales by Country (2021-2026) & (kg) Table 58. Asia Pacific Anthracycline APIs Sales by Country (2027-2032) & (kg) Table 59. South America, Middle East and Africa Anthracycline APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (kg) Table 60. South America, Middle East and Africa Anthracycline APIs Sales by Country (2021-2026) & (kg) Table 61. South America, Middle East and Africa Anthracycline APIs Sales by Country (2027-2032) & (kg) Table 62. Global Anthracycline APIs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Anthracycline APIs Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Anthracycline APIs Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Anthracycline APIs Revenue Market Share by Region (2021-2026) Table 66. Global Anthracycline APIs Revenue Market Share by Region (2027-2032) Table 67. Synbias-Gemini Company Information Table 68. Synbias-Gemini Business Overview Table 69. Synbias-Gemini Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Synbias-Gemini Anthracycline APIs Product Portfolio Table 71. Synbias-Gemini Recent Development Table 72. Intas Pharma Company Information Table 73. Intas Pharma Business Overview Table 74. Intas Pharma Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Intas Pharma Anthracycline APIs Product Portfolio Table 76. Intas Pharma Recent Development Table 77. MicroBiopharm Japan Company Information Table 78. MicroBiopharm Japan Business Overview Table 79. MicroBiopharm Japan Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. MicroBiopharm Japan Anthracycline APIs Product Portfolio Table 81. MicroBiopharm Japan Recent Development Table 82. TAPI Company Information Table 83. TAPI Business Overview Table 84. TAPI Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. TAPI Anthracycline APIs Product Portfolio Table 86. TAPI Recent Development Table 87. Humble Healthcaare Company Information Table 88. Humble Healthcaare Business Overview Table 89. Humble Healthcaare Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Humble Healthcaare Anthracycline APIs Product Portfolio Table 91. Humble Healthcaare Recent Development Table 92. Sterling Biotech Company Information Table 93. Sterling Biotech Business Overview Table 94. Sterling Biotech Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Sterling Biotech Anthracycline APIs Product Portfolio Table 96. Sterling Biotech Recent Development Table 97. Olon S.p.A. Company Information Table 98. Olon S.p.A. Business Overview Table 99. Olon S.p.A. Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Olon S.p.A. Anthracycline APIs Product Portfolio Table 101. Olon S.p.A. Recent Development Table 102. Lunan Pharmaceutical Company Information Table 103. Lunan Pharmaceutical Business Overview Table 104. Lunan Pharmaceutical Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Lunan Pharmaceutical Anthracycline APIs Product Portfolio Table 106. Lunan Pharmaceutical Recent Development Table 107. DZD (Heze) Pharmaceutical Company Information Table 108. DZD (Heze) Pharmaceutical Business Overview Table 109. DZD (Heze) Pharmaceutical Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. DZD (Heze) Pharmaceutical Anthracycline APIs Product Portfolio Table 111. DZD (Heze) Pharmaceutical Recent Development Table 112. Zhejiang Hisun Company Information Table 113. Zhejiang Hisun Business Overview Table 114. Zhejiang Hisun Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Zhejiang Hisun Anthracycline APIs Product Portfolio Table 116. Zhejiang Hisun Recent Development Table 117. Meiji Seika Pharma Company Information Table 118. Meiji Seika Pharma Business Overview Table 119. Meiji Seika Pharma Anthracycline APIs Sales (kg), Price (USD/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Meiji Seika Pharma Anthracycline APIs Product Portfolio Table 121. Meiji Seika Pharma Recent Development Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Anthracycline APIs Distributors List Table 125. Anthracycline APIs Customers List Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Anthracycline APIs Product Image Figure 2. Global Anthracycline APIs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anthracycline APIs Market Size (2021-2032) & (US$ Million) Figure 4. Global Anthracycline APIs Sales (2021-2032) & (kg) Figure 5. Global Anthracycline APIs Average Price (USD/g) & (2021-2032) Figure 6. Global Top 5 and 10 Anthracycline APIs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Doxorubicin API Image Figure 9. Daunorubicin API Image Figure 10. Epirubicin API Image Figure 11. Idarubicin API Image Figure 12. Pirarubicin API Image Figure 13. Other Image Figure 14. Global Anthracycline APIs Sales by Type (2021 VS 2025 VS 2032) & (kg) Figure 15. Global Anthracycline APIs Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Anthracycline APIs Sales Market Share by Type (2021-2032) Figure 17. Global Anthracycline APIs Revenue by Type (2021 VS 2025 VS 2032) & (kg) Figure 18. Global Anthracycline APIs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Anthracycline APIs Revenue Market Share by Type (2021-2032) Figure 20. Solid Tumors Image Figure 21. Hematologic Malignancies Image Figure 22. Others Image Figure 23. Global Anthracycline APIs Sales by Application (2021 VS 2025 VS 2032) & (kg) Figure 24. Global Anthracycline APIs Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Anthracycline APIs Sales Market Share by Application (2021-2032) Figure 26. Global Anthracycline APIs Revenue by Application (2021 VS 2025 VS 2032) & (kg) Figure 27. Global Anthracycline APIs Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Anthracycline APIs Revenue Market Share by Application (2021-2032) Figure 29. North America Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 30. North America Anthracycline APIs Sales Market Share by Country (2021-2032) Figure 31. U.S. Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 32. Canada Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 33. Mexico Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 34. Europe Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 35. Europe Anthracycline APIs Sales Market Share by Country (2021-2032) Figure 36. Germany Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 37. France Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 38. U.K. Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 39. Italy Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 40. Netherlands Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 41. Asia Pacific Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 42. Asia Pacific Anthracycline APIs Sales Market Share by Country (2021-2032) Figure 43. China Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 44. Japan Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 45. South Korea Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 46. Southeast Asia Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 47. India Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 48. Australia Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 49. South America, Middle East and Africa Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 50. South America, Middle East and Africa Anthracycline APIs Sales Market Share by Country (2021-2032) Figure 51. Brazil Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 52. South Africa Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 53. Saudi Arabia Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 54. Turkey Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 55. Argentina Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 56. UAE Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 57. Egypt Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 58. Chile Anthracycline APIs Sales and Growth Rate (2021-2032) & (kg) Figure 59. Global Anthracycline APIs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Anthracycline APIs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Anthracycline APIs Revenue (2021-2032) & (US$ Million) Figure 62. North America Anthracycline APIs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Anthracycline APIs Revenue (2021-2032) & (US$ Million) Figure 64. Europe Anthracycline APIs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Anthracycline APIs Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Anthracycline APIs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Anthracycline APIs Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Anthracycline APIs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Anthracycline APIs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Anthracycline APIs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Doxorubicin API
  • Daunorubicin API
  • Epirubicin API
  • Idarubicin API
  • Pirarubicin API
  • Other
Applications
  • Solid Tumors
  • Hematologic Malignancies
  • Others
Companies covered
  • Synbias-Gemini
  • Intas Pharma
  • MicroBiopharm Japan
  • TAPI
  • Humble Healthcaare
  • Sterling Biotech
  • Olon S.p.A.
  • Lunan Pharmaceutical
  • DZD (Heze) Pharmaceutical
  • Zhejiang Hisun
  • Meiji Seika Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anthracycline APIs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anthracycline APIs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anthracycline APIs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anthracycline APIs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anthracycline APIs Market Dynamics
  1. 2.1 Anthracycline APIs Industry Trends
  2. 2.2 Anthracycline APIs Industry Drivers
  3. 2.3 Anthracycline APIs Industry Opportunities and Challenges
  4. 2.4 Anthracycline APIs Industry Restraints
3 Anthracycline APIs Market by Manufacturers
  1. 3.1 Global Anthracycline APIs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anthracycline APIs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anthracycline APIs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anthracycline APIs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anthracycline APIs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anthracycline APIs Manufacturers, Product Type & Application
  7. 3.7 Global Anthracycline APIs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anthracycline APIs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anthracycline APIs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anthracycline APIs Tier 1, Tier 2, and Tier 3
4 Anthracycline APIs Market by Type
  1. 4.1 Anthracycline APIs Type Introduction
  2. 4.1.1 Doxorubicin API
  3. 4.1.2 Daunorubicin API
  4. 4.1.3 Epirubicin API
  5. 4.1.4 Idarubicin API
  6. 4.1.5 Pirarubicin API
  7. 4.1.6 Other
  8. 4.2 Global Anthracycline APIs Sales by Type
  9. 4.2.1 Global Anthracycline APIs Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Anthracycline APIs Sales by Type (2021-2032)
  11. 4.2.3 Global Anthracycline APIs Sales Market Share by Type (2021-2032)
  12. 4.3 Global Anthracycline APIs Revenue by Type
  13. 4.3.1 Global Anthracycline APIs Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Anthracycline APIs Revenue by Type (2021-2032)
  15. 4.3.3 Global Anthracycline APIs Revenue Market Share by Type (2021-2032)
5 Anthracycline APIs Market by Application
  1. 5.1 Anthracycline APIs Application Introduction
  2. 5.1.1 Solid Tumors
  3. 5.1.2 Hematologic Malignancies
  4. 5.1.3 Others
  5. 5.2 Global Anthracycline APIs Sales by Application
  6. 5.2.1 Global Anthracycline APIs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anthracycline APIs Sales by Application (2021-2032)
  8. 5.2.3 Global Anthracycline APIs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Anthracycline APIs Revenue by Application
  10. 5.3.1 Global Anthracycline APIs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anthracycline APIs Revenue by Application (2021-2032)
  12. 5.3.3 Global Anthracycline APIs Revenue Market Share by Application (2021-2032)
6 Global Anthracycline APIs Sales by Region
  1. 6.1 Global Anthracycline APIs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anthracycline APIs Sales by Region (2021-2032)
  3. 6.2.1 Global Anthracycline APIs Sales by Region (2021-2026)
  4. 6.2.2 Global Anthracycline APIs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anthracycline APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anthracycline APIs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anthracycline APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anthracycline APIs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anthracycline APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anthracycline APIs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anthracycline APIs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anthracycline APIs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anthracycline APIs Revenue by Region
  1. 7.1 Global Anthracycline APIs Revenue by Region
  2. 7.1.1 Global Anthracycline APIs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anthracycline APIs Revenue by Region (2021-2026)
  4. 7.1.3 Global Anthracycline APIs Revenue by Region (2027-2032)
  5. 7.1.4 Global Anthracycline APIs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anthracycline APIs Revenue (2021-2032)
  8. 7.2.2 North America Anthracycline APIs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anthracycline APIs Revenue (2021-2032)
  11. 7.3.2 Europe Anthracycline APIs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anthracycline APIs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anthracycline APIs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anthracycline APIs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anthracycline APIs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Synbias-Gemini
  2. 8.1.1 Synbias-Gemini Company Information
  3. 8.1.2 Synbias-Gemini Business Overview
  4. 8.1.3 Synbias-Gemini Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Synbias-Gemini Anthracycline APIs Product Portfolio
  6. 8.1.5 Synbias-Gemini Recent Developments
  7. 8.2 Intas Pharma
  8. 8.2.1 Intas Pharma Company Information
  9. 8.2.2 Intas Pharma Business Overview
  10. 8.2.3 Intas Pharma Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Intas Pharma Anthracycline APIs Product Portfolio
  12. 8.2.5 Intas Pharma Recent Developments
  13. 8.3 MicroBiopharm Japan
  14. 8.3.1 MicroBiopharm Japan Company Information
  15. 8.3.2 MicroBiopharm Japan Business Overview
  16. 8.3.3 MicroBiopharm Japan Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 MicroBiopharm Japan Anthracycline APIs Product Portfolio
  18. 8.3.5 MicroBiopharm Japan Recent Developments
  19. 8.4 TAPI
  20. 8.4.1 TAPI Company Information
  21. 8.4.2 TAPI Business Overview
  22. 8.4.3 TAPI Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 TAPI Anthracycline APIs Product Portfolio
  24. 8.4.5 TAPI Recent Developments
  25. 8.5 Humble Healthcaare
  26. 8.5.1 Humble Healthcaare Company Information
  27. 8.5.2 Humble Healthcaare Business Overview
  28. 8.5.3 Humble Healthcaare Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Humble Healthcaare Anthracycline APIs Product Portfolio
  30. 8.5.5 Humble Healthcaare Recent Developments
  31. 8.6 Sterling Biotech
  32. 8.6.1 Sterling Biotech Company Information
  33. 8.6.2 Sterling Biotech Business Overview
  34. 8.6.3 Sterling Biotech Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sterling Biotech Anthracycline APIs Product Portfolio
  36. 8.6.5 Sterling Biotech Recent Developments
  37. 8.7 Olon S.p.A.
  38. 8.7.1 Olon S.p.A. Company Information
  39. 8.7.2 Olon S.p.A. Business Overview
  40. 8.7.3 Olon S.p.A. Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Olon S.p.A. Anthracycline APIs Product Portfolio
  42. 8.7.5 Olon S.p.A. Recent Developments
  43. 8.8 Lunan Pharmaceutical
  44. 8.8.1 Lunan Pharmaceutical Company Information
  45. 8.8.2 Lunan Pharmaceutical Business Overview
  46. 8.8.3 Lunan Pharmaceutical Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lunan Pharmaceutical Anthracycline APIs Product Portfolio
  48. 8.8.5 Lunan Pharmaceutical Recent Developments
  49. 8.9 DZD (Heze) Pharmaceutical
  50. 8.9.1 DZD (Heze) Pharmaceutical Company Information
  51. 8.9.2 DZD (Heze) Pharmaceutical Business Overview
  52. 8.9.3 DZD (Heze) Pharmaceutical Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 DZD (Heze) Pharmaceutical Anthracycline APIs Product Portfolio
  54. 8.9.5 DZD (Heze) Pharmaceutical Recent Developments
  55. 8.10 Zhejiang Hisun
  56. 8.10.1 Zhejiang Hisun Company Information
  57. 8.10.2 Zhejiang Hisun Business Overview
  58. 8.10.3 Zhejiang Hisun Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Zhejiang Hisun Anthracycline APIs Product Portfolio
  60. 8.10.5 Zhejiang Hisun Recent Developments
  61. 8.11 Meiji Seika Pharma
  62. 8.11.1 Meiji Seika Pharma Company Information
  63. 8.11.2 Meiji Seika Pharma Business Overview
  64. 8.11.3 Meiji Seika Pharma Anthracycline APIs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Meiji Seika Pharma Anthracycline APIs Product Portfolio
  66. 8.11.5 Meiji Seika Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anthracycline APIs Value Chain Analysis
  2. 9.1.1 Anthracycline APIs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anthracycline APIs Production Mode & Process
  6. 9.2 Anthracycline APIs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anthracycline APIs Distributors
  9. 9.2.3 Anthracycline APIs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst